Statements (48)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:healthcare_organization
|
gptkbp:bfsLayer |
4
|
gptkbp:bfsParent |
gptkb:Hepacivirus
|
gptkbp:associated_with |
Liver cancer
Liver cirrhosis Chronic liver disease |
gptkbp:caused_by |
gptkb:healthcare_organization
|
gptkbp:duration |
8 to 12 weeks
|
gptkbp:genetic_diversity |
2
Higher genetic diversity than HCV-1 |
gptkbp:healthcare |
Requires ongoing surveillance
Significant in endemic regions |
https://www.w3.org/2000/01/rdf-schema#label |
HCV-2
|
gptkbp:is_a |
gptkb:virus
|
gptkbp:is_popular_in |
Lower than HCV-1
|
gptkbp:is_recognized_by |
1990s
|
gptkbp:is_vulnerable_to |
No vaccine available
|
gptkbp:region |
gptkb:Southeast_Asia
West Africa |
gptkbp:research_focus |
Vaccine development
Genetic studies Epidemiological studies Improved treatment regimens Understanding viral pathogenesis |
gptkbp:risk_factor |
Blood transfusions
Intravenous drug use Sexual transmission Tattooing with unsterile equipment Unsterile medical equipment |
gptkbp:social_responsibility |
Blood test
HCV antibody test HCVRNA test Can lead to chronic hepatitis Can lead to extrahepatic manifestations Can lead to liver failure Less common than HCV-1 globally More prevalent in certain populations |
gptkbp:symptoms |
Fatigue
Abdominal pain Jaundice |
gptkbp:transmission |
gptkb:healthcare_organization
|
gptkbp:treatment |
Antiviral therapy
Direct-acting antivirals Higher than 90% with modern therapies Interferon-based therapy |
gptkbp:type_of |
2a
2b 2c |